Johnson & Johnson aims for initial approval of nipocalimab to treat a wide range of patients with antibody-positive generalized myasthenia gravis.

Patsnap Bio, with its chemical modification search function, provides users with a powerful tool for exploring multidimensional nucleotide sequence information.

Merck has recently divulged advancements pertaining to two pivotal Phase 3 clinical trials, designated as KEYNOTE-867 and KEYNOTE-630.

at the ESC Congress, Bayer published the pooled analysis of the Phase III FINE-HEART study on finerenone, along with the latest data from the FINEARTS-HF trial.

Rallybio Unveils RLYB212's Phase 1 Exploratory Study Outcomes in Blood Clotting & Coagulation Dynamics.

Sep 3rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Bayer has disclosed the enrollment of the inaugural patient into the international Phase III SOHO-02 study, a randomized, open-label, multicenter clinical endeavor.

Merck KGaA, headquartered in Darmstadt, Germany, Reveals Initiation of Phase III Trial with Oral Cladribine for Treating Generalized Myasthenia Gravis (gMG), Marking First Patient Administration.

Biocon Biologics Achieves Market Access for Bmab 1200, a Biosimilar Candidate Akin to Stelara®, Across Europe, the UK, Canada, and Japan.

Jeune Aesthetics Reveals Encouraging Interim Safety & Efficacy Outcomes for KB301 in Phase 1, Targeting Lateral Eye Creases & Active Décolletage Wrinkles Reduction.

Neurocrine Biosciences Announces Encouraging Phase 2 Outcomes for NBI-1117568 in Adult Schizophrenia Patients, Demonstrating Potential Efficacy.

8.26-9.1 Global Drug R&D Progress & Pharmaceutical Transaction Trends.